IGI Logo

Emcure Pharmaceuticals is currently trading at Rs. 1386.65, up by 1.25 points or 0.09% from its previous closing of Rs. 1385.40 on the BSE.

The scrip opened at Rs. 1387.05 and has touched a high and low of Rs. 1398.10 and Rs. 1381.00 respectively. So far 3147 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 10 has touched a 52 week high of Rs. 1524.85 on 21-Aug-2025 and a 52 week low of Rs. 890.00 on 07-Apr-2025.

Last one week high and low of the scrip stood at Rs. 1429.35 and Rs. 1375.55 respectively. The current market cap of the company is Rs. 26274.76 crore.

The promoters holding in the company stood at 77.88%, while Institutions and Non-Institutions held 7.66% and 14.46% respectively.

Emcure Pharmaceuticals has launched Poviztra, semaglutide injection, across India. With this launch, Emcure becomes the first Indian company to exclusively distribute and commercialise Poviztra, a second brand of Novo Nordisk’s Semaglutide injection for weight management. 

Available in a once-weekly pen device in five strengths of 0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg and a maintenance dosing of 2.4 mg, the products will be priced starting Rs 8790 per month (4 weekly doses). It comes in a state-of-the-art pen device that provides the convenience of simple administration of precise dosing. Semaglutide injection (Poviztra) is supported by extensive clinical evidence from the STEP and SELECT clinical trial programmes and has demonstrated robust real-world use. Globally, the molecule has nearly a decade of market presence, 38 million patient-years of exposure, and a strong safety and efficacy profile backed by comprehensive data.

Poviztra is indicated as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kg/m2 or greater (obesity) or 27 kg/m2 or greater (overweight) in the presence of at least one weight-related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia). Poviztra is also indicated to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and either obesity or overweight. In clinical trials, the semaglutide formulation achieved weight loss of more than 20% in many patients.

Emcure Pharmaceuticals is one of the leading Indian pharmaceutical companies engaged in developing, manufacturing and globally marketing a broad range of pharmaceutical products across several major therapeutic areas.